¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"bovine malignant lymphoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hepatosplenic T-cell lymphoma
    °£ºñÀåT¼¼Æ÷¸²ÇÁÁ¾
  • histiocytic lymphoma
    Á¶Á÷±¸¸²ÇÁÁ¾
  • human T-cell lymphoma/leukemic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁÁ¾/¹éÇ÷º´¹ÙÀÌ·¯½º
  • immunoblastic lymphoma
    ¸é¿ª¸ð¼¼Æ÷¸²ÇÁÁ¾, ¸é¿ª¸ð±¸¸²ÇÁÁ¾
  • lymphoblastic lymphoma
    ¸²ÇÁ¸ð±¸¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾
  • lymphoma staging
    ¸²ÇÁÁ¾º´±â°áÁ¤
  • mantle cell lymphoma
    ¿ÜÅõ¼¼Æ÷¸²ÇÁÁ¾
  • marginal zone B lymphoma
    º¯¿¬ºÎB¼¼Æ÷¸²ÇÁÁ¾
  • NK/T cell lymphoma
    NK/T¼¼Æ÷¸²ÇÁÁ¾
  • non-Hodgkin¡¯s lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • subcutaneous panniculitis-like T-cell lymphoma
    ÇÇÇÏÁö¹æÃþ¿°À¯»çT¼¼Æ÷¸²ÇÁÁ¾
  • well-differentiated lymphocytic lymphoma
    °íºÐÈ­¸²ÇÁ±¸¸²ÇÁÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • malignant teratoma
    ¾Ç¼º±âÇüÁ¾
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • malignant chondroid syringoma
    ¾Ç¼º¿¬°ñ¶¡°üÁ¾
  • malignant mast mast reticulosis
    ¾Ç¼ººñ¸¸¼¼Æ÷±×¹°Áõ, ¾Ç¼ººñ¸¸¼¼Æ÷¼¼¸ÁÁõ
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immunoblastic lymphoma
    ¸é¿ª ¸ð¼¼Æ÷ ¸²ÇÁÁ¾
  • intestinal lymphoma
    À帲ÇÁÁ¾.
  • large cell anaplastic lymphoma
    ´ë¼¼Æ÷ ÅðÇ༺ ¸²ÇÁÁ¾
  • large cell lymphoma
    ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • leukemia/lymphoma
    ¹éÇ÷º´/¸²ÇÁÁ¾(ÛÜúìÜ»/¡­ðþ)
  • lymphoepithelioid lymphoma
    ¸²ÇÁÇ¥ÇÇ¾ç ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾.
  • lymphoma
    ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma cells
    ¸²ÇÁÁ¾¼¼Æ÷(¡­á¬øà)
  • lymphoma, Burkitts
    ¹öŶƮ ¸²ÇÁÁ¾
  • lymphoma,burkitts
    ¹öŶ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma,follicular
    ¿©Æ÷¼º¸²ÇÁÁ¾(æ¤øààõ¡­ðþ)
  • lymphoma,large cell, diffuse
    ´ë¼¼Æ÷¼º ¸²ÇÁÁ¾(ÓÞá¬øààõ ¡­ðþ)
  • lymphoma,lymphoblastic
    ¸²ÇÁ¸ð±¸¼º ¸²ÇÁÁ¾(¡­Ù½Ï¹àõ ¡­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MH Malignant Hyperthermia
NMS Neuroleptic Malignant Syndrome
CMM cell-mediated mutagenesis; cutaneous malignant melanoma
EMP electric membrane property; electromagnetic pulse; Embden-Meyerhof pathway; external membrane potent...
FMN first malignant neoplasm; flavin mononucleotide; frontomaxillonasal [suture]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MH Malignant Hyperpyrexia
MH Malignant Hyperthermia
MHS Malignant Hyperthermia Susceptible
MM Malignant Melanoma
MMMT Malignant Mixed Mesodermal Tumor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
    1. ¿ÜÀ½¿¡ »ý±â´Â °¡Àå Áß¿äÇÑ º´º¯ÀÎ Á¾¾çÀÇ ÀÏÁ¾À¸·Î ¿ÜÀ½ÀÇ ¾Ç¼º Èæ»öÁ¾Àº µå¹°°í, ¿©¼º¿¡¼­ °üÂûµÇ´Â Èæ»öÁ¾ÀÇ 2%°¡ ¿ÜÀ½¿¡¼­ ¹ß»ýÇÑ´Ù. 2. »ö¼Ò ¼¼Æ÷¿¡ »ý±ä ¾Ç¼º Á¾¾ç. 3. Ç¥ÇǼº Èæ»ö±¸¿Í ±× Àü±¸Ã¼·ÎºÎÅÍ ¹ß»ýÇÏ´Â ´ë´ÜÈ÷ ¾Ç¼ºÀÎ Á¾¾çÀÌ´Ù. ¸ðµç ¾Ç¼º Á¾¾ç Áß 1%°¡ ¾Ç¼º Èæ»öÁ¾ÀÌ´Ù. ÀÌÁß 90%´Â ¿ÜÇÇ¿¡ ³ªÅ¸³ª°í 10%´Â ÇǺΠ¿Ü¿¡ ³ªÅ¸³­´Ù. ¸ðµç ¾Ç¼º Èæ»öÁ¾ Áß 1%´Â ±¸°­ ³»¿¡¼­ ¹ß»ýÇÑ´Ù. ¹ß»ýÀ²ÀÌ Áõ°¡µÇ´Â °Íó·³ º¸ÀÌ´Â ÀÌ·± Á¾¾çÀÇ Æ¯È÷ ³ª»Û Á¡Àº ¸²ÇÁ ¼øÈ¯°ú Ç÷¾× ¼øÈ¯À» ÅëÇØ ºü¸£°Ô ÀüÀ̵Ǵ °ÍÀÌ´Ù.
  • malignant mesenchymoma
    ¾Ç¼º ³»¹è¿±Á¾
  • malignant myopia
    ¾Ç¼º ±Ù½Ã
    Ã༺ ±Ù½Ã·Î¼­ ¾ÈÃàÀåÀÌ ±¼Àý·Â¿¡ ºñÇØ ³Ê¹« ±æ¾î ÆòÇà ±¤¼±ÀÌ ¸Á¸· ¾Õ¿¡ ÃÊÁ¡À» ¸ÎÀ¸¹Ç·Î ¼±¸íÇÏÁö ¾ÊÀº »óÀ» ¸Î°Ô µÈ´Ù. °úµµÇÑ Á¶Àý ¹× ´« ¸ðÀ½, ½Ã½Å°æ À¯µÎÀÇ ºÎÁ¾, ³»ºÐºñ ÀÌ»ó, Æí½Ä µîÀÌ ¿øÀÎÀ̶ó°í ÇÏ´Â ÁÖÀåµµ ÀÖÀ¸³ª ºÐ¸íÄ¡ ¾Ê´Ù.
  • malignant neoplasm
    ¾Ç¼º ½Å»ý¹°
  • malignant oxyphilic adenoma
    ¾Ç¼º È£»ê¼º ¼±Á¾
  • malignant plasma cell
    ¾Ç¼º ÇüÁú ¼¼Æ÷
  • malignant pleomorphic adenoma
    ¾Ç¼º ´ÙÇü¼º ¼±Á¾
  • malignant salivary gland tumor
    ¾Ç¼º Ÿ¾×¼± Á¾¾ç
  • malignant tumor
    ¾Ç¼º Á¾¾ç
    Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû, È­ÇÐÀû, »ý¹°ÇÐÀûÀÎ ¾Ï¿ø¼º ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç ¹«Á¦ÇÑÀÇ ¼¼Æ÷ ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§ Á¶Á÷À» ÆÄ±«, ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷ ¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ ¾Ç¾×ÁúÀ» ¾ß±â½ÃÄÑ Á×À½ÀÇ À§ÇèÀ» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
  • non-malignant
    ºñ¾Ç¼º
  • nonodontogenic malignant tumor jaw
    ºñÄ¡¾Æ¼º ¾Ç¼º Á¾¾ç
  • rare malignant granulomatoses
    Èñ±ÍÇÑ ¾Ç¼º À°¾ÆÁ¾Áõ
  • ulcerated malignant tumor
    ±Ë¾ç¼º ¾Ç¼º Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
malignant hypertension A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
malignant hyperthermia A severe form of fever that occurs as a reaction to certain anaesthetic agents and muscle relaxants. Malignant hyperthermia is an inherited autosomal dominant condition.
Inheritance: autosomal dominant.
(27 Sep 1997)
malignant jaundice Jaundice associated with high fever and delirium; seen in severe hepatitis and other diseases of the liver with severe functional failure.
Synonym: malignant jaundice.
(05 Mar 2000)
malignant lentigo melanoma <tumour> A melanoma arising from a malignant lentigo.
(05 Mar 2000)
malignant liver tumours <radiology> EPITHELIAL TUMORS, hepatocellular, hepatoblastoma (7%), hepatocellular carcinoma (HCC) (75%), cholangiocellular (6%), cholangiocarcinomarcinoma, cystadenocarcinoma, MESENCHYMAL TUMORS, tumours of blood vessels, angiosarcoma, haemangioendothelioma, other tumours, embryonal sarcoma, fibrosarcoma, TUMORS OF MUSCLE TISSUE, leiomyosarcoma, rhabdomyosarcoma, MISCELLANEOUS, carcinosarcoma, teratoma, yolk sac tumour, carcinoid, squamous carcinoma, primary lymphoma see: benign liver tumours
(12 Dec 1998)
malignant lymphadenosis An obsolete term for malignant lymphoma.
(05 Mar 2000)
malignant malnutrition A nutritional deficiency illness in children who are not getting enough protein, this results in anaemia, poor growth, weakness, and oedema (which isparticularly characterised by a pronounced pot belly). Infamine-stricken regions, children typically develop kwashiorkor rightafter they are weaned.
(09 Oct 1997)
malignant melanoma <oncology, tumour> A malignant tumour which arises from the pigment producing cells (melanosomes) of the deeper layers of the skin (or the eye). Melanoma is the leading cause of death attributable to skin lesions. Described as an irregular dark skin lesion that may have areas of varying colour. Often greater than 6 mm in diameter.
(27 Sep 1997)
malignant melanoma: gallium imaging <radiology> Greater than50% sensitivity for primary and metastatic sites: 73% sensitivity if lesion is greater than 2 cm, 17% sensitivity if less than 2 cm, see: gallium: indications malignant melanoma
(12 Dec 1998)
malignant melanoma in situ A melanoma limited to the epidermis and composed of nests of atypical melanocytes and scattered single cells extending into the upper epidermis; local excision is curative although the lesion, if untreated, may soon invade the dermis. Malignant lentigo may be considered a slowly progressive type of malignant melanoma in situ.
(05 Mar 2000)
malignant melanoma: staging <radiology> Clark staging: level I: all tumour cells above basement membrane (in situ), level II: tumour extends to papillary dermis, level III: tumour extends to interface between papillary and reticular dermis, level IV: tumour extends between bundles of collagen of reticular dermis, level V: tumour invasion of sucutaneous tissue (87% metastases) Breslow staging: thin: less than 0.75 mm depth of invasion, intermediate: 0.76 - 3.99 mm depth of invasion, thick: greater than 4 mm depth of invasion see: malignant melanoma
(12 Dec 1998)
malignant meningioma <tumour> Meningioma that either invades brain parenchyma or metastasizes.
(05 Mar 2000)
malignant mesothelioma <oncology, tumour> A mesothelioma is a tumour of the lining of the lung and chest cavity, known as the pleura. Benign mesotheliomas do occur but are much more rare than the malignant type. Malignant mesothelioma affects men more commonly and about 80% of cases have a history for prior exposure to asbestos.
Symptoms include chest pain, shortness of breath, cough and weight loss.
(27 Sep 1997)
malignant midline reticulosis An obsolete term for polymorphic reticulosis
(05 Mar 2000)
malignant mixed mullerian tumour A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells.
Synonym: malignant mixed mullerian tumour.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á